Management of occult malignant pleural disease firstly detected at thoracotomy for non-small cell lung cancer patients
Authors:
- 1 October 2017
- journal article
- research article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 9 (10) , 3851-3858
Abstract
Background: The current study was to investigate the risk factors of occult malignant pleural disease (MPD) detected at thoracotomy and the outcomes of surgical intervention for these non-small cell lung cancer (NSCLC) patients with or without MPD. Methods: We reviewed 2,093 consecutive NSCLC patients who underwent thoracotomy from January 2006 to January 2015. We used univariate and multivariate statistics to analyze the associations between clinicopathological variables and occurrence of occult MPD. Survival probability was estimated by the Kaplan-Meier method. Results: 5.26% (110/2,093) MPD was observed for these NSCLC patients with 28% of 5-year estimated survival rate. Age ≤50 (P=0.055), high CEA level (P=0.006), advanced N stage (P=0.005), adenocarcinoma (P=0.001) and pleural invasion (P=0.041) were detected to be independent risk factors for the occult MPD. Combination of these five factors, 0.756 of area under curve (AUC) was shown by the integrated prediction model test. Based on the optimal cut-off value (risk score =2.795), low-risk patients have better prognosis than the high-risk patients (median survival time 61.4 months vs. not reached, Pvs. 51.1%, PConclusions: We summarized that a new prediction model including 5-risk factors of age, carcinoembryonic antigen (CEA), N stage, adenocarcinoma and pleural invasion was provided to diagnose MPD for the NSCLC patients and primary lesion resection greatly contributed for these MPD patients.Keywords
This publication has 20 references indexed in Scilit:
- Surgical Intervention for Non–Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004Journal of Thoracic Oncology, 2015
- Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancerJournal of Carcinogenesis, 2015
- Recent Advances in the Diagnosis and Management of Malignant Pleural EffusionsMayo Clinic Proceedings, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patientsPathology and Oncology Research, 2005
- Diagnostic Value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 Assays in Pleural Effusions: Analysis of 116 Cases and Review of the LiteratureThe Oncologist, 2005
- The Physiologic Evaluation of Patients With Lung Cancer Being Considered for Resectional Surgery*Chest, 2003
- Malignant minor pleural effusion detected on thoracotomy for patients with non–small cell lung cancer: is tumor resection beneficial for prognosis?The Annals of Thoracic Surgery, 2002
- Prognostic implication of Ki-67 immunostaining in treating subclinical pleural cancer found at thoracotomy in lung cancer patientsThe Annals of Thoracic Surgery, 2001
- Prognostic value of pleural effusion in patients with non-small cell lung cancer.1997